The research project is led by
Grand Challenges Explorations funds researchers worldwide to explore ideas that might break the mold in how we solve persistent global health and development challenges. Approximately 3% of applications are awarded in Phase I, and of those, approximately 1 in 10 are awarded a Phase II grant. The receipt of the Phase II award represents success in Phase I and the foundation’s assessment that the proposed work is a technology likely to advance child health.
Dr. Tarr, who is also the Melvin E. Carnahan Professor of Pediatrics and Professor of Molecular Microbiology at the School of Medicine, said: “Abnormal gut permeability is increasingly recognized as being associated with a diversity of human disorders, including stunting and malnutrition in children in resource-poor regions of the world. There are no easily administered and reliable tests of gut permeability, which is an important measure of gut function. We plan to use MediBeacon’s fluorescence detection agents and technology to monitor gut permeability, without the need to draw blood or collect any specimens.”
MediBeacon has developed proprietary tracer agents and detection methods to measure gut permeability.
HC2 also announced that MediBeacon was recently the recipient of a
“Our investments through Pansend Life Sciences are focused on developing and providing unique and innovative solutions in healthcare,” said
Learn more about HC2 and its portfolio companies at www.hc2.com.
About Grand Challenges Explorations
Grand Challenges Explorations is a
MediBeacon’s mission is to commercialize biocompatible optical diagnostic agents for physiological monitoring, surgical guidance, and imaging of pathological disease in the human population. Several product concepts in these arenas are contained in the MediBeacon Intellectual Property estate. MediBeacon’s portfolio includes a renal function system that uses an optical skin sensor combined with a proprietary fluorescent tracer agent that glows in the presence of light. This system, currently in human trials, provides clinicians continuous real-time monitoring of a patient’s kidney function.
Learn more about MediBeacon at www.medibeacon.com
Cautionary Statement Regarding Forward-Looking Statements
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This release contains, and certain oral statements made by our representatives from time to time may contain, forward-looking statements. Generally, forward-looking statements include information describing actions, events, results, strategies and expectations and are generally identifiable by use of the words “believes,” “expects,” “intends,” “anticipates,” “plans,” “seeks,” “estimates,” “projects,” “may,” “will,” “could,” “might,” or “continues” or similar expressions. The forward-looking statements in this press release include without limitation statements regarding our expectation regarding building shareholder value. Such statements are based on the beliefs and assumptions of HC2's management and the management of HC2's subsidiaries. The Company believes these judgments are reasonable, but you should understand that these statements are not guarantees of performance or results, and the Company’s actual results could differ materially from those expressed or implied in the forward-looking statements due to a variety of important factors, both positive and negative, that may be revised or supplemented in subsequent reports on Forms 10-K, 10-Q and 8-K. Such important factors include, without limitation, issues related to the restatement of our financial statements; the fact that we have historically identified material weaknesses in our internal control over financial reporting, and any inability to remediate future material weaknesses; capital market conditions; the ability of HC2's subsidiaries to generate sufficient net income and cash flows to make upstream cash distributions; volatility in the trading price of HC2 common stock; the ability of HC2 and its subsidiaries to identify any suitable future acquisition opportunities; our ability to realize efficiencies, cost savings, income and margin improvements, growth, economies of scale and other anticipated benefits of strategic transactions; difficulties related to the integration of financial reporting of acquired or target businesses; difficulties completing pending and future acquisitions and dispositions; effects of litigation, indemnification claims, and other contingent liabilities; changes in regulations and tax laws; and risks that may affect the performance of the operating subsidiaries of HC2. These risks and other important factors discussed under the caption “Risk Factors” in our most recent Annual Report on Form 10-K filed with the
You should not place undue reliance on forward-looking statements. All forward-looking statements attributable to HC2 or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. All such statements speak only as of the date made, and HC2 undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
For information on
HC2 Holdings, Inc., please contact: Andrew G. BackmanManaging Director Investor Relations & Public Relations email@example.com 212-339-5836